Lisa Cooney, MD
Internal Medicine · Wasilla, AKNPI 1578522694
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,203 and has fallen 77.8% since, to $267 in 2024. Among internal medicine clinicians in AK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$569
- AbbVie$255
- Merck$211
- Lilly USA, LLC$183
- GSK$155
- Pfizer$147
- plus $2K from 25 others
What the payments were for
- Food & beverage$2,96298%
- Education$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $569 |
| AbbVie(2 entities) | 14 | $255 |
| Merck | 12 | $211 |
| Lilly USA, LLC | 12 | $183 |
| GSK | 9 | $155 |
| Pfizer | 8 | $147 |
| Novo Nordisk | 7 | $141 |
| Amgen | 6 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $114 |
| Insulet Corporation | 2 | $97 |
| Sanofi-aventis U.S. LLC | 6 | $96 |
| Johnson & Johnson(2 entities) | 5 | $93 |
| Exact Sciences | 4 | $91 |
| Novartis | 4 | $83 |
| E.r. Squibb & Sons, L.L.C. | 4 | $83 |
| Alkermes, Inc. | 4 | $71 |
| Astellas Pharma US Inc | 3 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $54 |
| Nestle Healthcare Nutrition Inc. | 2 | $50 |
| Azurity Pharmaceuticals, Inc. | 2 | $45 |
| Bayer | 2 | $42 |
| Boehringer Ingelheim | 2 | $36 |
| Medtronic | 1 | $34 |
| Neurocrine Biosciences, Inc. | 2 | $31 |
| Philips North America LLC | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
How this compares
$3,021 in reported general payments places this provider in the 90th percentile of 124 internal medicine providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 43 | $69,460 |
| OzempicSemaglutide | 31 | $48,936 |
| JanuviaSitagliptin Phosphate | 35 | $47,298 |
| JardianceEmpagliflozin | 25 | $29,836 |
| EliquisApixaban | 26 | $29,834 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 26 | $27,675 |
| XareltoRivaroxaban | 13 | $21,974 |
| MyrbetriqMirabegron | 16 | $18,148 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $16,439 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $14,732 |
| Repatha SyringeEvolocumab | 13 | $14,385 |
| Dexlansoprazole DrDexlansoprazole | 19 | $9,449 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 12 | $7,610 |
| SynthroidLevothyroxine Sodium | 84 | $6,848 |
| LinzessLinaclotide | 12 | $6,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $183 | $69,46043 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $36 | $57,51151 claims |
| Novo NordiskOzempic | $141 | $48,93631 claims |
| MerckJanuvia | $211 | $47,29835 claims |
| PfizerEliquis | $147 | $29,83426 claims |
| Johnson & JohnsonXarelto | $93 | $21,97413 claims |
| Astellas Pharma US IncMyrbetriq | $57 | $18,14816 claims |
| AbbVieSynthroid, Linzess, Armour Thyroid | $255 | $15,858136 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $23 | $7,61012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 124 internal medicine providers in Alaska.
Other internal medicine in Wasilla
- David BarnesWasilla$11K
- John BostonWasilla$6K
- Loetta Horswill WoodsWasilla$106
- Loretta LeeAnchorage$8K
- Andrew CapGlennallen$7K
- Susan HeverlingAnchorage$6K
- Laurie MontanoAnchorage$6K
- Michele O FallonAnchorage$6K
- Alvaro RosalesAnchorage$4K
- Robin MillerAnchorage$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.